Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Matching personalised therapies to patients in the IMPACT trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 353
Rating:

Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA

Prof Tsimberidou speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the IMPACT study that showed using molecular tests of tumours to select targeted therapy resulted in better patient outcomes.

She describes how, of the 1,307 patients with at least one genetic change in the cancer, the 3-year overall survival rate was 15% in the matched targeted group compared to 7% in the non-matched group.

The 10-year overall survival rate was 6% for the matched group and 1% in the non-matched group.

For more on these results, watch her present the results in a press session here, and read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence